150+ Patents, $113 Million Raised, 4 Employees: Inside the Company Betting It Doesn't Need to Run Its Own Trials

Terran Biosciences holds the only granted patent on a new form of MDMA, was first to patent new salts of psilocybin, and has licensing deals with Sanofi and Pierre Fabre — all reportedly with a team of four. We looked at how a company this small built a pipeline this large, and what it's actually betting on.

Most of the companies in our money rankings are running their own clinical trials — Compass, Definium, GH Research, all spending tens of millions of dollars a year proving their own compound works in their own patients. Terran Biosciences, a private company we'd only mentioned in passing until now, is playing a different game entirely: it patents new chemical forms of drugs whose underlying mechanism other companies have already spent hundreds of millions proving, then either licenses that intellectual property out or uses it to pursue a faster FDA pathway than a from-scratch approval would require. As of July 2026, it reportedly did this with a team of four employees.

The Founder and the Bet

Terran was founded in 2017 by Dr. Samuel Clark, who holds an MD and PhD from Columbia and a neuroscience degree from MIT, starting with a $10,000 seed check. Clark is credited with more than 200 patent applications across his career — a figure describing his own personal output, distinct from Terran's separate claim to "more than 150 patents" in the company's own portfolio as of last year. The company has since raised $113 million from institutional investors, according to PitchBook and Crunchbase data.

Own the Chemistry, Not Necessarily the Trial

Terran's clearest strategic move is in the drugs everyone already knows: file for a new patentable salt, co-crystal, or polymorph of a compound whose therapeutic mechanism is already established, then use that novelty — not a fresh efficacy trial — as the basis for both a patent and an accelerated FDA filing under the 505(b)(2) pathway, which lets a sponsor rely in part on the FDA's prior findings about a related, already-approved drug.

MDMA hemifumarate — Terran holds US Patent 11,958,821, the world's first composition-of-matter patent on a new salt/polymorph of MDMA, specifically for PTSD. If an MDMA product is ever approved via the standard hydrochloride salt, Terran's plan is to use pharmacokinetic bridging studies — not a full new efficacy trial — to bring its own version to market roughly five years behind, per the company's own timeline.
Psilocybin salts — In December 2023, Terran received notice of allowance for patents on what it describes as the first new salts and co-crystals of psilocybin in history (psilocybin HCl and psilocybin edisylate), alongside a filed psilocybin Drug Master File with the FDA.
DMT and 5-MeO-DMT prodrugs — a separate notice of allowance covers what Terran describes as the first orally active prodrugs of DMT and 5-MeO-DMT.
University of Maryland, Baltimore license — in July 2025, Terran took an exclusive worldwide license on a portfolio of psychedelic-therapeutic patents and data from UMB, broadening the IP base further.

The Two Pharma Deals

Rather than developing everything itself, Terran has also acquired late-stage assets from larger companies and re-licensed them:

Sanofi (April 2022) — worldwide exclusive rights to two undisclosed late-stage CNS pipeline assets that had already generated 4 FDA Investigational New Drug applications and more than 104 clinical studies across upward of 15,000 subjects. Deal terms (upfront, milestones, royalties) were not disclosed.
Pierre Fabre (June 2023) — worldwide exclusive rights to idazoxan, a selective alpha-2 receptor antagonist already tested in multiple Phase 3 studies and dosed in more than 1,000 patients, plus a portfolio of related compounds. Phase 2 proof-of-concept data showed idazoxan nearly doubling the symptom improvement of standard antipsychotic therapy alone as an add-on in schizophrenia.

TerXT: Chasing an Already-Approved Drug

Terran's most-watched asset may be TerXT, a longer-acting prodrug version of xanomeline-trospium — the same mechanism as Bristol Myers Squibb's Cobenfy, approved by the FDA on September 26, 2024 as the first new-mechanism schizophrenia drug in roughly 70 years. TerXT comes in two forms: a once-daily oral version and a multi-month long-acting injectable, both designed to improve on Cobenfy's twice-daily dosing. Terran's stated plan was to begin two Phase 1 trials once Cobenfy cleared the FDA, then pursue its own 505(b)(2) filing once BMS's five-year market exclusivity lapses. We could not confirm whether those Phase 1 trials have actually started as of this writing, roughly two years after Cobenfy's approval — worth watching, and worth a follow-up once there's a public update.

The Diagnostics Side

Terran also runs a genuinely distinct business line: in December 2023, it received the industry's first FDA clearance for software analyzing neuromelanin-sensitive MRI scans (NM-101), a cloud-based tool that turns around a full report in under an hour and is aimed at aiding diagnosis of Parkinson's disease, and potentially Alzheimer's and schizophrenia, as an adjunct to standard imaging.

The Honest Read

Terran's model is genuinely different from most of the companies we cover — it's closer to a chemistry-and-licensing shop than a conventional clinical-stage biotech, and that's a real strength: it's raised meaningfully less than public peers while building one of the field's larger patent portfolios, largely by riding on efficacy data other companies already generated. The tradeoff is equally real: a new salt form doesn't carry its own efficacy data, and 505(b)(2) approval still requires the FDA to accept that bridging studies are sufficient — nothing here is guaranteed to work just because the underlying mechanism (MDMA, psilocybin, xanomeline-trospium) has already cleared a trial once, in a different chemical form, at a different company.

This is business reporting, not medical or investment advice. No compound or product discussed here is FDA-approved for any indication except where explicitly noted (Cobenfy, held by Bristol Myers Squibb, not Terran). Patent grants and notices of allowance are not the same as regulatory approval.